Spero Therapeutics(US:SPRO) Globenewswire·2025-11-13 21:05Core Insights - Spero Therapeutics reported financial results for Q3 2025, highlighting a net loss of $7.4 million, a significant reduction from a net loss of $17.1 million in Q3 2024, indicating improved financial performance [8] - The company is advancing its investigational oral antibiotic, tebipenem HBr, with plans for FDA submission in Q4 2025, potentially offering a new treatment option for complicated urinary tract infections [2][6] Financial Performance - Total revenue for Q3 2025 was $5.4 million, down from $13.5 million in Q3 2024, primarily due to decreased collaboration revenue with GSK and a decline in grant revenue [8] - Research and development expenses decreased to $8.6 million in Q3 2025 from $26.9 million in the same period in 2024, attributed to reduced clinical expenses related to the PIVOT-PO trial and lower costs associated with the SPR720 program [8] - General and administrative expenses were $4.2 million in Q3 2025, down from $5.2 million in Q3 2024, mainly due to reduced personnel-related costs [14] Pipeline Developments - Tebipenem HBr is being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, and has shown non-inferiority to intravenous imipenem-cilastatin in the PIVOT-PO trial [3][7] - The PIVOT-PO trial results indicated an overall success rate of 58.5% for tebipenem HBr compared to 60.2% for imipenem-cilastatin, with a safety profile consistent with other carbapenem antibiotics [7] - The SPR720 program for nontuberculous mycobacterium pulmonary disease has been discontinued following a review of Phase 2a and Phase 1 trial data [4] Cash Position - As of September 30, 2025, Spero had cash and cash equivalents of $48.6 million, which is expected to fund operations into 2028 [14]